Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Outcomes
100%
Progressive multifocal Leukoencephalopathy
100%
Long-term Survivors
100%
Modified Rankin Scale
66%
Disability Scale
66%
Highly Active Antiretroviral Therapy (HAART)
33%
HIV Patients
33%
Non-associated
16%
Ventricular Enlargement
16%
Cytotoxic T Lymphocytes
16%
White Matter
16%
Disability
16%
CD8+
16%
Immunosuppressed
16%
Non-Hodgkin Lymphoma
16%
1-year Survival
16%
HIV-negative
16%
Activities of Daily Living
16%
Demyelinating Diseases
16%
Experimental Therapeutics
16%
Cerebellar Lesion
16%
Specific Treatment
16%
Ribbon
16%
Cellular Immune Response
16%
Persistent Symptoms
16%
Neurological Improvement
16%
Severe Disabilities
16%
Significant Disabilities
16%
Subcortical Atrophy
16%
Living Independently
16%
JC Polyomavirus (JCPyV)
16%
Leukomalacia
16%
Medicine and Dentistry
Progressive Multifocal Leukoencephalopathy
100%
Human Immunodeficiency Virus
50%
Highly Active Antiretroviral Therapy
33%
CD8 Antigen
16%
Magnetic Resonance Imaging
16%
Immunotherapy
16%
Non-Hodgkin Lymphoma
16%
JC Virus
16%
Cytotoxic T-Cell
16%
Clinically Isolated Syndrome
16%
Experimental Therapy
16%
Cellular Immunity
16%
Cerebellum Injury
16%
Leukomalacia
16%
Pharmacology, Toxicology and Pharmaceutical Science
Progressive Multifocal Leukoencephalopathy
100%
HIV
50%
CD8 Antigen
16%
Nonhodgkin Lymphoma
16%
Immunotherapy
16%
Demyelinating Disease
16%
JC Virus
16%
Cerebellum Injury
16%
Leukomalacia
16%
Neuroscience
Progressive Multifocal Leukoencephalopathy
100%
Human Immunodeficiency Virus
50%
Magnetic Resonance Imaging
16%
JC Virus
16%
Immunotherapy
16%
Demyelinating Disease
16%
T Cell
16%
CD8
16%
Non-Hodgkin Lymphoma
16%